Who owns the site
GLP Chart is owned and operated by John Samaras, an independent editorial operator based in Austin, Texas, focused on the US weight-loss telehealth market. Single-owner LLC for accounting and tax purposes. No outside investors, no venture capital, no preferred partnerships with any program in the chart. No equity in any of the 25 reviewed companies.
Who decides what gets scored and how
Editorial decisions are made by John alone, with input from the medical reviewer when that role is filled. (The reviewer role is open as of mid-2026; see the about page for the recruitment status.) Scoring uses five published dimensions (pricing transparency, cancellation terms, onboarding, medication options, member outcomes) weighted equally. The framework is documented at the methodology page and applied identically to every program in the chart.
Programs do not see their score before publication. We do not adjust scores in response to partnership outreach. We do not run programs as “featured” or sponsored regardless of how much they offer.
Where the money comes from
The revenue mix as of 2026:
- Affiliate commissions: roughly 90% of revenue. When a reader clicks a “Visit” link to a partner program and signs up, we receive a one-time referral fee from the program’s affiliate network. The fee is the same regardless of which partner we recommend. Disclosed inline on every page that contains affiliate links via the “How we make money” line, and at /affiliate-disclosure/.
- Email newsletter sponsorships: roughly 5% of revenue once the newsletter scales past 10,000 subscribers. Currently zero (newsletter recently launched). Future sponsorships will be labeled SPONSORED in every issue and will never affect chart scoring.
- Research syndication and press licensing: roughly 5% projected. Bloomberg, STAT, Endpoints and similar outlets can license our quarterly Price Index data with attribution. Inquire at press@glpchart.com.
We do not accept: paid placement, sponsored content, gift cards or kickbacks from programs, hospitality from sponsors, equity in programs we cover or any other form of value transfer that would compromise editorial independence.
The editorial firewall
Affiliate-network managers and program-side business-development staff contact us routinely. They are answered by the same person who edits the site, which is necessary at our scale. The firewall is procedural rather than personnel-based:
- Scores are set by the published methodology applied to verifiable data. Discretion at the margin is documented and reviewed.
- No partnership conversation can change a score that’s already published. We have declined this explicitly when asked, every time.
- If a program offers higher commission terms in exchange for placement, the program’s commission rate is irrelevant to editorial because the editorial score is set first and the commercial terms are negotiated only with programs whose score is already locked.
- If we ever fail this firewall, we will publish the failure on the site and refund any affiliate revenue earned during the compromised period. We have not failed it to date.
Programs we decline to cover
We do not list programs that:
- Refuse to publish their pricing publicly
- Refuse to disclose their compounding pharmacy partner
- Make claims about unapproved peptides (AOD-9604, BPC-157, MOTS-c, etc.)
- Use deceptive comparison advertising against named competitors
- Have outstanding state pharmacy-board sanctions or FDA warning letters
- Operate without a state-licensed prescribing clinician for the patient’s state of residence
This is a non-trivial list of programs and we lose affiliate revenue by declining them. We do it anyway because the chart’s value depends on excluding programs we wouldn’t personally recommend to family.
Disclosed conflicts and prior affiliations
John has no current employment relationship with any program in the chart, no current consulting role with any pharmaceutical manufacturer, no current investment position (public or private) in any company covered. Prior background is in consumer-product analysis and SaaS, not healthcare or biotech.
If circumstances change (consulting work, investment, employment), the change will be disclosed on this page within 30 days and any affected coverage will be reviewed.
Member feedback sourcing
Member-feedback sub-scores (the “What we like / What to watch” blocks on each program review) are compiled from public sources: Trustpilot, Reddit (program-specific subreddits and r/Semaglutide, r/Wegovy_Weightloss, r/Zepbound) and program-specific forum communities. We do not pay for review access. We do not solicit reviews. We do not filter for positive feedback; the most-frequently-mentioned complaints are surfaced explicitly under “What to watch” on each review.
Editorial contact
For editorial corrections or factual disputes: hello@glpchart.com. We respond within 48 hours on business days and publicly correct anything wrong, with a date-stamped note on the original page.
For press, licensing or quotable-stat requests: press@glpchart.com. See the press kit.
For programs that want to correct their listing or appeal a score: same email. The score won’t change without verifiable evidence. A factual error will be corrected immediately.
